{"prompt": "['CONFIDENTIAL', 'Table of Contents', 'PROTOCOL SUMMARY', '6', 'ABBREVIATIONS', '7', '1.0 INTRODUCTION', '9', '1.1.', 'BACKGROUND AND RATIONALE', '9', '1.2.', 'DEVICE DESCRIPTION', '12', '2.0 BENEFITS/RISKS', '13', '2.1.', 'BENEFITS', '13', '2.2.', 'RISKS', '13', '3.0 STUDY OBJECTIVES', '17', '3.1.', 'PRIMARY OBJECTIVES', '17', '3.2', 'SECONDARY OBJECTIVES', '17', '4.0 STUDY DESIGN', '18', '4.1.', 'SELECTION OF SUBJECTS', '18', '4.2.', 'SUBJECT SELECTION CRITERIA', '18', '4.3.', 'INFORMED CONSENT', '19', '5.0 STUDY PROCEDURES', '19', '5.1 BLINDING AND SHAM-CONDITION.', '19', '5.1.1. Blinding', '19', '5.1.2 Sham condition:', '20', '5.2.', 'VISIT SCHEDULE', '20', '5.2.1 Screening and informed consent', '21', '5.2.2 Baseline assessment', '22', '5.2.3 Randomization', '23', '5.2.4 Treatment Visits', '23', '5.2.6 Occupational therapy, physiotherapy and home exercise program', 'during the active treatment and follow-up periods of the trial', '24', '6.0 ANALYSIS PLAN', '25', '6.1 POWER ANALYSIS AND DATA POOLING WITH NICHE ACTIVE TRIAL ARM', 'RESULTS', '25', '6.2 ANALYSIS SCHEDULE', '26', '6.3 ANALYSIS POPULATIONS', '26', '6.4', 'STRATA AND COVARIATES', '27', '6.5', 'SIGNIFICANCE LEVEL', '27', '6.6', 'DATA HANDLING METHODS', '27', '6.7 SAFETY ANALYSES', '28', 'ADVERSE Events', '28', 'UNANTICIPATED ADVERSE DEVICE Events (UADE)', '29', 'DEVICE-RELATED ADVERSE Events (DRAE)', '29', '6.7.1 Primary Safety Analysis', '29', '6.8 ASSESSMENT OF BLINDING SUCCESS', '29', 'Page 4 of 57']['CONFIDENTIAL', 'SUBJECT BLINDING SUCCESS', '29', 'OUTCOME ASSESSMENT THERAPIST BLINDING SUCCESS', '29', '7.0 MONITORING AND QUALITY ASSURANCE', '30', 'INDEPENDENT MONITORING OF SOURCE DATA AND SAFETY', '30', 'ADVERSE EVENT REPORTING GUIDELINE', '31', 'ADVERSE Event', '31', '8.0 REFERENCES (ALPHABETICAL ORDER)', '33', 'APPENDIX A NBT PROCEDURES', '38', 'GENERAL', '38', 'ELECTROMYOGRAPHY', '38', 'MRI TO HEAD CO-REGISTRATION', '38', 'BASELINE, TREATMENT VISITS', '38', 'HEALTHY HEMISPHERE', '39', 'HAND AREA MOTOR MAPPING', '39', 'Attach mapping coil (Nexstim Focal Coil)', '39', 'Identifying the rough location of hand motor area', '39', 'Initial motor threshold measurement for defining intensity for motor mapping: 40', 'Mapping of hand motor area and localization of m. EDC hotspot', '40', 'THERAPY DELIVERY', '41', \"Attach the TMS coil appropriate for the subject's randomization group\", '(Nexstim Trial Coil)', '42', 'Motor threshold measurement for defining intensity for rTMS therapy', '42', 'RTMS stimulation', '42', 'OFF-LINE ANALYSIS', '42', 'APPENDIX B TASK ORIENTED UPPER LIMB THERAPY PROTOCOL', '43', 'Page 5 of 57']\n\n###\n\n", "completion": "END"}